灵麦快讯LMLB118 【洞察】白血病的“春天”还会远么? - AML中国市场概览

欢迎分享，转载有版权, 请登录 lingmed.net/reports 下载全文

本周灵麦医药推荐一篇灵麦的市场分析报告 — 急性骨髓性白血病的中国市场现状

Linkedbio 灵佰市场分析:

灵麦分析团队通过对文献搜索分析（包括公司年报和其他新闻评论等）及一线访谈帮助我们的客户完成市场项目分析工作， 包括产品在中国的市场销量预估，交易的估值和竞争情报分析报告等

急性骨髓性白血病（Acute myeloid leukemia, AML）是一种骨髓性造血芽细胞（而非淋巴性芽细胞）异常增殖的血液恶性肿瘤。作为成年人最常见的急性白血病，全球男女性AML终生患病风险（Lifetime Risk）分别约为1/250和1/300。尽管相较于其他的癌症，AML还是较为罕见（在美国，约占因癌症而死亡的人数的1.2%），但其发病率会随着年龄的增加而增加。考虑到‘年龄’是AML很重要的一个危险因素，未来庞大的“老年化”中国市场必然亦是兵家必争之地。 

• 现阶段AML中国流行病学信息及药物治疗方法

• 中国市场AML相关重点药物有哪些？其历史销售额及定价为多少？

• 中国AML总市场规模是多少？

• 中国AML领域重点公司及其产品线

• 43个正在积极寻求中国合作伙伴的AML全球项目总结

Can Spring Be Far Behind? - The Chinese Market Research Overview for AML

 

This week Lingmed shares with you a research article on AML China market.

 

Linkedbio Analysis:

Lingmed analyst team conducts desk researches and interviews to get insights on China market, we provide tailored product China market sizing analysis, deal valuation and competitive landscape reports to our clients

 

Acute Myeloid Leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. As the the most common acute leukemia affecting adults, the lifetime risk of getting AML is about 1 in 250 for men and  about 1 in 300 for women. Although AML is a relatively rare disease, accounting for roughly 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages. Considering “aging” and large Chinese population, China must be a crucial market for business.

• The Chinese Epidemiology information and treatment regimen

• The sales and pricing for key products in China

• The overall market size for AML

• Key companies for AML

• 43 Worldwide Opportunities looking for Chinese partners summary

想要下载完整报告? 

请登录 www.lingmed.net/reports

或点击下方“阅读原文”马上下载